Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03612401 · ClinicalTrials.gov registry record · Early Phase 1
Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron
A Early Phase 1 study of Spinal Cord Injuries and Cognitive Change, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03612401: Completed Early Phase 1 study of Spinal Cord Injuries and Cognitive Change, sponsored by The University of Texas Health Science Center at San Antonio.
NCT03612401 is a Early Phase 1 study of Spinal Cord Injuries and Cognitive Change that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03612401, a Early Phase 1 study of Spinal Cord Injuries and Cognitive Change, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
We propose to test the hypothesis that cognition will improve with substitution of mirabegron for the anticholinergic agent (AC) in elderly persons with spinal cord injury (SCI) who require neurogenic bladder (NGB) treatment.
Primary Outcome
Wechsler Memory Scale, 4th edition (WMS-IV) subtest
Conditions Studied
Interventions
- DRUG Mirabegron
Study Locations (1)
Texas
- South Texas Veterans Health Care System, Audie L. Murphy Hospital - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2021-03-31 |
| Phase | Early Phase 1 |
What the finished NCT03612401 record still lists
NCT03612401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (67% lower).
The record links to 3 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which Mirabegron is the first listed.
NCT03612401 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03612401 about?
NCT03612401 is a clinical study titled "Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron". We propose to test the hypothesis that cognition will improve with substitution of mirabegron for the anticholinergic agent (AC) in elderly persons with spinal cord injury (SCI) who require neurogenic bladder (NGB) treatment.
What is the current status of trial NCT03612401?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2018-12-05. Estimated completion is 2021-03-31.
What conditions does trial NCT03612401 study?
This clinical trial studies the following conditions: Spinal Cord Injuries, Cognitive Change, Neurogenic Bladder.
What interventions are being tested in trial NCT03612401?
The interventions under investigation include: Mirabegron (DRUG).
Who is sponsoring clinical trial NCT03612401?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03612401 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03612401's enrollment target sits among peer trials
20 126th of 202 higher than 66 of 202 other Spinal Cord Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Spinal Cord Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury
RECRUITING · Early Phase 1
-
Transformation of Paralysis to Stepping
ACTIVE NOT RECRUITING · Early Phase 1
-
Transdermal Administration by a Novel Wireless Iontophoresis Device
COMPLETED · Early Phase 1
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
RECRUITING · NA
-
Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy